Latest Breaking News On - செயல்பாடுகள் தகவல் - Page 2 : comparemela.com

Axsome Therapeutics Reports First Quarter 2021 Financial

AXS-07 for migraine, NDA submission (2Q 2021) AXS-05 for smoking cessation, FDA meeting (3Q 2021) AXS-05 for MDD, commercial launch, if approved (2H 2021) Clinical Trial Readouts: Clinical Trial Initiations: Upcoming Scientific Conferences International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021 American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021 American Headache Society (AHS) annual meeting, June 3-6, 2021 Upcoming Investor Conferences BofA Health Care Conference, May 11, 2021 (to be webcast) RBC Capital Markets Global Healthcare Conference, May 18, 2021 (to be webcast) UBS Global Healthcare Virtual Conference, May 24, 2021 (to be webcast) William Blair Growth Stock Conference, June 3, 2021 (to be webcast) First Quarter 2021 Financial Results

New yorkUnited statesHerriot tabuteauMark jacobsonCenters for diseaseAxsome therapeutics incInternational society for pharmacoeconomicsDrug administrationMental health americaOutcomes researchAmerican society for clinical psychopharmacologyMental health monthAmerican headache societyBofa health care conferenceDuke universityPriority review

Weatherford Announces First-Quarter 2021 Results

Share this article Share this article HOUSTON, May 5, 2021 /PRNewswire/ Weatherford International plc (OTC Pink: WFTLF) ( Weatherford or the Company ) announced today its results for the first quarter of 2021. Revenues for the first quarter of 2021 were $832 million, a decline of 1% sequentially and 32% year-on-year. Reported operating loss was $13 million in the first quarter of 2021, compared to an operating loss of $107 million in the fourth quarter of 2020 and an operating loss of $822 million in the first quarter of 2020. The Company s first-quarter 2021 net loss was $116 million, compared to a net loss of $200 million in the fourth quarter of 2020 and a net loss of $966 million in the first quarter of 2020. First-quarter 2021 cash flows provided by operations were $74 million, compared to cash flows provided by operations of $22 million in the fourth quarter of 2020 and cash flows provided by operations of $30 million in the first quarter of 2020. Capital expenditur

United statesUnited kingdomNorth seaOceans generalAfrica asiaGirish saligramMohammed topiwalaKelley hughesGlobal communicationsWeatherford internationalExchange commissionCompany annual report on formWeatherford drilling servicesTubular running servicesChief executive officerNorth america

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Published: Mar 01, 2021 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020. “The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer’s disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “So far this year, we have submitted to the FDA the NDA for AX

New yorkUnited statesAnn arborHerriot tabuteauMark jacobsonKevin laliberteAxsome therapeutics incDrug administrationUniversity of north carolinaUniversity of michiganProduct developmentProduct development at dova pharmaceuticalsDuke universityChief executive officerBreakthrough therapyNew drug application

Weatherford Announces Fourth-Quarter and Full-Year 2020 Results

Share this article Share this article HOUSTON, Feb. 17, 2021 /PRNewswire/ Weatherford International plc (OTC Pink: WFTLF) ( Weatherford or the Company ) announced today its results for the fourth quarter and full-year 2020. Revenues for the fourth quarter of 2020 were $842 million, compared to revenue of $985 million and $261 million in the Predecessor and Successor periods of the fourth quarter of 2019, respectively. Reported operating loss was $107 million in the fourth quarter of 2020, compared to an operating loss of $316 million and operating income of $1 million in the Predecessor and Successor periods of the fourth quarter of 2019, respectively. The Company s fourth-quarter 2020 net loss was $200 million, compared to net income of $5.3 billion and a net loss of $26 million in the Predecessor and Successor periods of the fourth quarter of 2019, respectively. Fourth-quarter 2020 cash flows provided by operations were $22 million, compared to cash flows used in operations

Vaca muertaSan juanCaspian seaOceans generalUnited statesSaudi arabiaNorth dakotaNorth seaAfrica asiaSebastian pellizzerGirish saligramKelley hughesGlobal communicationsNational oil companiesNational oil companyCompany vero

En 2020, el SAT realizó menos devoluciones a los contribuyentes

En 2020, el SAT realizó menos devoluciones a los contribuyentes
laverdadnoticias.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laverdadnoticias.com Daily Mail and Mail on Sunday newspapers.

United statesRevenue of theOperations informationNew presidentGoogle newsஒன்றுபட்டது மாநிலங்களில்செயல்பாடுகள் தகவல்புதியது ப்ரெஸிடெஂட்கூகிள் செய்தி